Lay­offs hit pri­vate gene ther­a­py star­tups, mi­graine biotech Sat­suma as in­dus­try squeeze doesn’t let up

Two small gene ther­a­py mak­ers and a biotech work­ing on an in­ves­ti­ga­tion­al mi­graine drug have let em­ploy­ees go. The moves add to a broad­er year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.